BACKGROUND: Idiopathic Parkinson's disease can present with symptoms similar to those of multiple system atrophy or progressive supranuclear palsy. We aimed to assess whether metabolic brain imaging combined with spatial covariance analysis could accurately discriminate patients with parkinsonism who had different underlying disorders. METHODS: Between January, 1998, and December, 2006, patients from the New York area who had parkinsonian features but uncertain clinical diagnosis had fluorine-18-labelled-fluorodeoxyglucose-PET at The Feinstein Institute for Medical Research. We developed an automated image-based classification procedure to differentiate individual patients with idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. For each patient, the likelihood of having each of the three diseases was calculated by use of multiple disease-related patterns with logistic regression and leave-one-out cross-validation. Each patient was classified according to criteria defined by receiver-operating-characteristic analysis. After imaging, patients were assessed by blinded movement disorders specialists for a mean of 2.6 years before a final clinical diagnosis was made. The accuracy of the initial image-based classification was assessed by comparison with the final clinical diagnosis. FINDINGS: 167 patients were assessed. Image-based classification for idiopathic Parkinson's disease had 84% sensitivity, 97% specificity, 98% positive predictive value (PPV), and 82% negative predictive value (NPV). Imaging classifications were also accurate for multiple system atrophy (85% sensitivity, 96% specificity, 97% PPV, and 83% NPV) and progressive supranuclear palsy (88% sensitivity, 94% specificity, 91% PPV, and 92% NPV). INTERPRETATION: Automated image-based classification has high specificity in distinguishing between parkinsonian disorders and could help in selecting treatment for early-stage patients and identifying participants for clinical trials. FUNDING: National Institutes of Health and General Clinical Research Center at The Feinstein Institute for Medical Research. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
BACKGROUND:Idiopathic Parkinson's disease can present with symptoms similar to those of multiple system atrophy or progressive supranuclear palsy. We aimed to assess whether metabolic brain imaging combined with spatial covariance analysis could accurately discriminate patients with parkinsonism who had different underlying disorders. METHODS: Between January, 1998, and December, 2006, patients from the New York area who had parkinsonian features but uncertain clinical diagnosis had fluorine-18-labelled-fluorodeoxyglucose-PET at The Feinstein Institute for Medical Research. We developed an automated image-based classification procedure to differentiate individual patients with idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. For each patient, the likelihood of having each of the three diseases was calculated by use of multiple disease-related patterns with logistic regression and leave-one-out cross-validation. Each patient was classified according to criteria defined by receiver-operating-characteristic analysis. After imaging, patients were assessed by blinded movement disorders specialists for a mean of 2.6 years before a final clinical diagnosis was made. The accuracy of the initial image-based classification was assessed by comparison with the final clinical diagnosis. FINDINGS: 167 patients were assessed. Image-based classification for idiopathic Parkinson's disease had 84% sensitivity, 97% specificity, 98% positive predictive value (PPV), and 82% negative predictive value (NPV). Imaging classifications were also accurate for multiple system atrophy (85% sensitivity, 96% specificity, 97% PPV, and 83% NPV) and progressive supranuclear palsy (88% sensitivity, 94% specificity, 91% PPV, and 92% NPV). INTERPRETATION: Automated image-based classification has high specificity in distinguishing between parkinsonian disorders and could help in selecting treatment for early-stage patients and identifying participants for clinical trials. FUNDING: National Institutes of Health and General Clinical Research Center at The Feinstein Institute for Medical Research. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Authors: Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning Journal: Mov Disord Date: 2003-05 Impact factor: 10.338
Authors: Klaus Seppi; Christoph Scherfler; Eveline Donnemiller; Irene Virgolini; Michael F H Schocke; Georg Goebel; Katherina J Mair; Sylvia Boesch; Christian Brenneis; Gregor K Wenning; Werner Poewe Journal: Arch Neurol Date: 2006-08
Authors: Thomas Eckert; Andrew Feigin; Daniel E Lewis; Vijay Dhawan; Steven Frucht; David Eidelberg Journal: Mov Disord Date: 2007-01-15 Impact factor: 10.338
Authors: I Litvan; J J Hauw; J J Bartko; P L Lantos; S E Daniel; D S Horoupian; A McKee; D Dickson; C Bancher; M Tabaton; K Jellinger; D W Anderson Journal: J Neuropathol Exp Neurol Date: 1996-01 Impact factor: 3.685
Authors: Alexandra Gaenslen; Barbara Unmuth; Jana Godau; Inga Liepelt; Adriana Di Santo; Katherine Johanna Schweitzer; Thomas Gasser; Hans-Jürgen Machulla; Matthias Reimold; Kenneth Marek; Daniela Berg Journal: Lancet Neurol Date: 2008-04-03 Impact factor: 44.182
Authors: Martin Niethammer; Chris C Tang; Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Christine V Sapan; David Eidelberg; Matthew J During; Michael G Kaplitt; Andrew Feigin Journal: JCI Insight Date: 2017-04-06
Authors: Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir Journal: Neurology Date: 2014-01-22 Impact factor: 9.910
Authors: Vincent A Jourdain; Chris C Tang; Florian Holtbernd; Christian Dresel; Yoon Young Choi; Yilong Ma; Vijay Dhawan; David Eidelberg Journal: JCI Insight Date: 2016-09-22
Authors: Raquel C Gardner; Adam L Boxer; Andrew Trujillo; Jacob B Mirsky; Christine C Guo; Efstathios D Gennatas; Hilary W Heuer; Eric Fine; Juan Zhou; Joel H Kramer; Bruce L Miller; William W Seeley Journal: Ann Neurol Date: 2013-03-27 Impact factor: 10.422